DBV Technologies reported $200K in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
BioCryst Pharmaceuticals USD 395.61M 209K Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Galectin Therapeutics USD 93.42M 9.08M Jun/2024
Halozyme Therapeutics USD 2.94B 1.01B Sep/2026
Incyte USD 28.42M 994K Jun/2026
Insmed USD 544.86M 1.35M Sep/2026
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 536.27M 749K Sep/2026
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
United Therapeutics USD 100M 100M Jun/2024